"Sou\u010Dek, Miroslav" . "Adherence a perzistence se zam\u011B\u0159en\u00EDm na l\u00E9\u010Dbu hypertenzn\u00EDch pacient\u016F" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "I" . "CZ - \u010Cesk\u00E1 republika" . . "6" . . "Adherence and persistence with a focus on the treatment of hypertensive patients"@en . . "59539" . "RIV/00159816:_____/13:00060829" . "Adherence and persistence with a focus on the treatment of hypertensive patients"@en . . "Insufficient adherence of patients to treatment is a serious problem and it is monitored most frequently in hypertensive patients. The possibilities of increasing adherence to long\u2011term treatment include mainly the motivation and education of patients, simple dosage regimes, telephone consultations and involving the patient in the treatment process (self\u2011monitoring), but it also means provi-ding information about the consequences of failure to adhere to the treatment process. Other possibilities can include new dosage forms which increase the bio\u00ADlogical availability of medicines, reduce the variability of absorption, and thus allow for achieving their more stable levels. It is possible to take advantage of fixed combinations which can improve adherence. Some new dosage forms simplify the therapy for patients and make it more pleasant. One of the latest innovations is for example, orodispersible dosage forms, which have been recently introduced in the therapy of arterial hypertension. In order to improve the adherence of patients to hypertension treatment it is necessary to use all means available adjusted to the individual needs of patients."@en . "RIV/00159816:_____/13:00060829!RIV14-MZ0-00159816" . . "Adherence a perzistence se zam\u011B\u0159en\u00EDm na l\u00E9\u010Dbu hypertenzn\u00EDch pacient\u016F"@cs . . . "Adherence a perzistence se zam\u011B\u0159en\u00EDm na l\u00E9\u010Dbu hypertenzn\u00EDch pacient\u016F" . "orodispersible tablets; hypertension; persistence; adherence"@en . . "1"^^ . . "4"^^ . "59" . "[D53918017559]" . . . . . "Nedostate\u010Dn\u00E1 adherence pacient\u016F k l\u00E9\u010Db\u011B je v\u00FDznamn\u00FDm probl\u00E9mem a u hypertenzn\u00EDch pacient\u016F je sledov\u00E1na nej\u010Dast\u011Bji. Mezi mo\u017Enosti zv\u00FD\u0161en\u00ED adherence k dlouhodob\u00E9 l\u00E9\u010Db\u011B pat\u0159\u00ED p\u0159edev\u0161\u00EDm motivace a edukace pacient\u016F, jednoduch\u00E9 d\u00E1vkovac\u00ED re\u017Eimy, telefonick\u00E9 konzultace a vta\u017Een\u00ED pacienta do l\u00E9\u010Debn\u00E9ho procesu (self\u2011monitoring), ale je to tak\u00E9 sezn\u00E1men\u00ED s n\u00E1sledky nedodr\u017Eov\u00E1n\u00ED l\u00E9\u010Debn\u00E9ho procesu. Dal\u0161\u00ED mo\u017Enost\u00ED mohou b\u00FDt nov\u00E9 l\u00E9kov\u00E9 formy, kter\u00E9 zvy\u0161uj\u00ED bio\u00ADlogickou dostupnost l\u00E9\u010Div, omezuj\u00ED variabilitu vst\u0159eb\u00E1v\u00E1n\u00ED, a umo\u017En\u00ED tak dosa\u017Een\u00ED jejich stabiln\u011Bj\u0161\u00EDch hladin. S v\u00FDhodou lze pou\u017E\u00EDt fixn\u00ED kombinace, kter\u00E9 mohou zlep\u0161ovat adherenci. N\u011B\u00ADkte\u00ADr\u00E9 nov\u00E9 l\u00E9kov\u00E9 formy p\u0159in\u00E1\u0161ej\u00ED pacient\u016Fm zjednodu\u0161en\u00ED a zp\u0159\u00EDjemn\u011Bn\u00ED terapie. Mezi posledn\u00ED novinky pat\u0159\u00ED nap\u0159. orodisperzn\u00ED l\u00E9kov\u00E9 formy, nov\u011B zav\u00E1d\u011Bn\u00E9 i do terapie arteri\u00E1ln\u00ED hypertenze. Ke zlep\u0161en\u00ED adherence nemocn\u00FDch k l\u00E9\u010Db\u011B hypertenze je t\u0159eba vyu\u017E\u00EDt v\u0161ech dostupn\u00FDch prost\u0159edk\u016F p\u0159izp\u016Fsoben\u00FDch individu\u00E1ln\u00EDm pot\u0159eb\u00E1m pacient\u016F."@cs . . "Nedostate\u010Dn\u00E1 adherence pacient\u016F k l\u00E9\u010Db\u011B je v\u00FDznamn\u00FDm probl\u00E9mem a u hypertenzn\u00EDch pacient\u016F je sledov\u00E1na nej\u010Dast\u011Bji. Mezi mo\u017Enosti zv\u00FD\u0161en\u00ED adherence k dlouhodob\u00E9 l\u00E9\u010Db\u011B pat\u0159\u00ED p\u0159edev\u0161\u00EDm motivace a edukace pacient\u016F, jednoduch\u00E9 d\u00E1vkovac\u00ED re\u017Eimy, telefonick\u00E9 konzultace a vta\u017Een\u00ED pacienta do l\u00E9\u010Debn\u00E9ho procesu (self\u2011monitoring), ale je to tak\u00E9 sezn\u00E1men\u00ED s n\u00E1sledky nedodr\u017Eov\u00E1n\u00ED l\u00E9\u010Debn\u00E9ho procesu. Dal\u0161\u00ED mo\u017Enost\u00ED mohou b\u00FDt nov\u00E9 l\u00E9kov\u00E9 formy, kter\u00E9 zvy\u0161uj\u00ED bio\u00ADlogickou dostupnost l\u00E9\u010Div, omezuj\u00ED variabilitu vst\u0159eb\u00E1v\u00E1n\u00ED, a umo\u017En\u00ED tak dosa\u017Een\u00ED jejich stabiln\u011Bj\u0161\u00EDch hladin. S v\u00FDhodou lze pou\u017E\u00EDt fixn\u00ED kombinace, kter\u00E9 mohou zlep\u0161ovat adherenci. N\u011B\u00ADkte\u00ADr\u00E9 nov\u00E9 l\u00E9kov\u00E9 formy p\u0159in\u00E1\u0161ej\u00ED pacient\u016Fm zjednodu\u0161en\u00ED a zp\u0159\u00EDjemn\u011Bn\u00ED terapie. Mezi posledn\u00ED novinky pat\u0159\u00ED nap\u0159. orodisperzn\u00ED l\u00E9kov\u00E9 formy, nov\u011B zav\u00E1d\u011Bn\u00E9 i do terapie arteri\u00E1ln\u00ED hypertenze. Ke zlep\u0161en\u00ED adherence nemocn\u00FDch k l\u00E9\u010Db\u011B hypertenze je t\u0159eba vyu\u017E\u00EDt v\u0161ech dostupn\u00FDch prost\u0159edk\u016F p\u0159izp\u016Fsoben\u00FDch individu\u00E1ln\u00EDm pot\u0159eb\u00E1m pacient\u016F." . "1"^^ . . "Adherence a perzistence se zam\u011B\u0159en\u00EDm na l\u00E9\u010Dbu hypertenzn\u00EDch pacient\u016F"@cs . "0042-773X" .